VCYT Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Veracyte Inc (VCYT) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The company shows strong financial growth, positive analyst sentiment, and stable technical indicators. Despite the recent price decline, the stock's fundamentals and growth trajectory make it a solid long-term investment.
The MACD is positive and contracting, indicating a potential stabilization in price. RSI is neutral at 32.833, and moving averages are converging, suggesting no strong directional trend. Key support is at 33.759, close to the current post-market price of 33.85, which could act as a floor for the stock.
Financial performance in Q4 2025 showed strong revenue growth of 18.55% YoY and a massive net income increase of 704.79% YoY. EPS also surged by 733.33%.
Guggenheim raised the price target to $50, maintaining a Buy rating, reflecting confidence in the company's future.
High gross margin of 72.07%, up 9.68% YoY, indicates operational efficiency.
Recent price decline of -2.39% in the regular market and -3.00% in pre-market trading may indicate short-term selling pressure.
No recent news or significant insider/hedge fund trading activity to act as immediate catalysts.
In Q4 2025, Veracyte reported revenue of $140.64M, up 18.55% YoY. Net income surged to $41.15M, up 704.79% YoY. EPS increased to 0.5, up 733.33% YoY. Gross margin improved to 72.07%, up 9.68% YoY, showcasing strong financial health and growth potential.
Guggenheim raised the price target to $50 from $45 and maintained a Buy rating. This reflects positive sentiment and confidence in the company's growth trajectory.
